According to Wired, the founder and chief executive officer of the Foresite Capital Management. Jim Tananbaum has been in more than 20 ventures that have had success in the healthcare industry. Amira Pharmaceuticals, Amerigroup, and Jazz Pharmaceuticals are the real examples that he has spent his money and time and made it succeed. As a manager in GelTex Pharmaceuticals and Theravance, his broad knowledge and potential have made them excellent.
In school matters, he got his MD from the Harvard Medical School and his MBA from the Harvard Business School. In Yale University, he acquired his BS and BSEE. He gives advice to boards and committees in the Yale School of Engineering and also at the Harvard University.
The Foresite Capital recently hired Molly He, a venture partner who has vast experience in the healthcare sector. She has experience in pharmaceutical and genomic research and development. Her research has managed to come up with helpful next-generation sequencing that, according to Jim Tananbaum will guide in genomics and the development of new drugs that are focused on dealing with specific ailments. He believes that Molly will bring development to Foresite Capital and take it to new heights in the innovation of protein reagent and its improvement.
Dr. Tananbaum has plans to increase his investment boundaries to grow the capital in the healthcare sector. He is a seasoned, dynamic and open minded individual who is yet to give a more scientific contribution to the drug and research industry. He is yet to discover more drugs to be used by sick people.
His company gives capital to the healthcare investors, and he makes his expertise noted. The labor that he has contributes to the invention of drugs. The Foresite company has the best products and services to offer their clients. After manufacture, they make an effort to analyze the quality of the drugs to ensure they are safe when used globally. His firm headquarters is located in San Francisco.
Dr. Tananbaum has plans to make the drug manufacturing industry competitive, and he would like people to buy original, non-generic drugs tested and proved to be efficient.